Rakuten Investment Management Inc. Sells 20,069 Shares of Zoetis Inc. $ZTS

Rakuten Investment Management Inc. trimmed its stake in Zoetis Inc. (NYSE:ZTS) by 25.6% during the 4th quarter, HoldingsChannel reports. The fund owned 58,321 shares of the company’s stock after selling 20,069 shares during the quarter. Rakuten Investment Management Inc.’s holdings in Zoetis were worth $7,347,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in ZTS. Brighton Jones LLC increased its position in shares of Zoetis by 180.4% during the fourth quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock valued at $754,000 after acquiring an additional 2,978 shares in the last quarter. Empowered Funds LLC increased its position in shares of Zoetis by 6.2% during the first quarter. Empowered Funds LLC now owns 11,293 shares of the company’s stock valued at $1,859,000 after acquiring an additional 657 shares in the last quarter. Intech Investment Management LLC increased its position in shares of Zoetis by 17.2% during the first quarter. Intech Investment Management LLC now owns 8,347 shares of the company’s stock valued at $1,374,000 after acquiring an additional 1,224 shares in the last quarter. Sivia Capital Partners LLC increased its position in shares of Zoetis by 73.8% during the second quarter. Sivia Capital Partners LLC now owns 3,348 shares of the company’s stock valued at $522,000 after acquiring an additional 1,422 shares in the last quarter. Finally, Glenview Trust co increased its position in shares of Zoetis by 11.8% during the second quarter. Glenview Trust co now owns 4,780 shares of the company’s stock valued at $745,000 after acquiring an additional 506 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Stock Performance

Shares of ZTS opened at $79.28 on Wednesday. The company has a debt-to-equity ratio of 2.80, a current ratio of 3.15 and a quick ratio of 1.91. Zoetis Inc. has a one year low of $72.38 and a one year high of $164.32. The firm has a market capitalization of $33.24 billion, a P/E ratio of 13.15, a PEG ratio of 1.25 and a beta of 0.75. The business has a fifty day moving average of $95.41 and a 200 day moving average of $113.49.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, May 7th. The company reported $1.53 EPS for the quarter, missing the consensus estimate of $1.60 by ($0.07). Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The firm had revenue of $2.26 billion during the quarter, compared to the consensus estimate of $2.30 billion. During the same period in the previous year, the firm earned $1.48 EPS. The business’s revenue was up 2.9% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. As a group, sell-side analysts anticipate that Zoetis Inc. will post 6.88 EPS for the current year.

Zoetis Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Monday, July 20th will be issued a $0.53 dividend. The ex-dividend date of this dividend is Monday, July 20th. This represents a $2.12 annualized dividend and a dividend yield of 2.7%. Zoetis’s payout ratio is presently 35.16%.

Insider Buying and Selling

In other Zoetis news, Director Paul Bisaro purchased 2,000 shares of the firm’s stock in a transaction on Wednesday, May 13th. The shares were acquired at an average cost of $75.88 per share, for a total transaction of $151,760.00. Following the completion of the transaction, the director owned 27,862 shares of the company’s stock, valued at approximately $2,114,168.56. The trade was a 7.73% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Frank A. Damelio purchased 6,650 shares of the firm’s stock in a transaction on Wednesday, May 13th. The stock was acquired at an average price of $75.39 per share, for a total transaction of $501,343.50. Following the completion of the transaction, the director directly owned 21,458 shares of the company’s stock, valued at approximately $1,617,718.62. This trade represents a 44.91% increase in their position. The SEC filing for this purchase provides additional information. Insiders bought 11,650 shares of company stock valued at $886,384 over the last 90 days. Company insiders own 0.22% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently weighed in on ZTS shares. Stifel Nicolaus reduced their price target on shares of Zoetis from $105.00 to $95.00 and set a “hold” rating for the company in a research report on Friday, May 22nd. JPMorgan Chase & Co. lowered their target price on shares of Zoetis from $190.00 to $130.00 and set an “overweight” rating on the stock in a research note on Friday, May 8th. Weiss Ratings cut shares of Zoetis from a “sell (d+)” rating to a “sell (d)” rating in a research note on Friday. UBS Group lowered their target price on shares of Zoetis from $130.00 to $99.00 and set a “neutral” rating on the stock in a research note on Friday, May 8th. Finally, Leerink Partners restated a “market perform” rating on shares of Zoetis in a research note on Tuesday, March 10th. Six research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $133.92.

Zoetis News Roundup

Here are the key news stories impacting Zoetis this week:

• Negative Sentiment: The flood of class-action reminders highlights alleged investor harm and creates another headline risk for Zoetis, which can weigh on sentiment while litigation moves forward. Article Title
• Negative Sentiment: Several law firms allege securities-law violations tied to the same class period, reinforcing uncertainty around prior disclosures and potentially keeping pressure on the stock. Article Title
• Neutral Sentiment: The company’s recent earnings backdrop remains a separate concern: Zoetis previously missed both EPS and revenue estimates, which may continue to influence investor caution.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.